Introduction: The main objective was to evaluate feasibility, toxicity and biochemical control rates of salvage external beam radiotherapy (EBRT) in recurrent localized prostate cancer after high-intensity focused ultrasound (HIFU) as primary therapy. Patients and Methods: A total of 24 patients who underwent salvage EBRT after 1 or 2 HIFU sessions and with a minimum post-treatment follow-up of 24 months were retrospectively evaluated. Primary endpoints were toxicity and biochemical disease-free survival (bDFS, defined according to the ASTRO Phoenix definition). Results: Median follow-up was 40.3 months. Gastrointestinal toxicity was low. Acute genitourinary (GU) toxicity grade ≤II rate was 45.8%, with only few patients presenting grade III (8.3%) and grade IV (4.2%) toxicity. Late grade ≥III GU toxicity was registered in 16.7% of patients. The 3-year bDFS rate was 77.8%. Patients achieving a nadir prostate-specific antigen (nPSA) of ≤0.35 ng/ml after EBRT had significantly higher bDFS (3-year bDFS: 87.7 vs. 50%, respectively; p = 0.001). Achieving nPSA ≤0.35 ng/ml was the only factor independently associated to long-term bDFS both on univariate (p = 0.01) and multivariate analysis (HR 7.06, p = 0.039). Conclusions: Salvage EBRT after HIFU failure is feasible and allows to obtain satisfactory biochemical control rates, especially in patients attaining a nPSA ≤0.35 ng/ml after EBRT.

Keywords:
High-intensity focused ultrasound relapse, Nadir prostate-specific antigen, Recurrent prostate adenocarcinoma, Salvage external beam radiotherapy, Toxicity
1.
Lukka H, Waldron T, Chin J, Mayhew L, Warde P, Winquist E, Rodrigues G, Shayegan B, on behalf of the Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol 2011;23:117-127.
2.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
3.
Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
4.
Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A: First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008;53:1194-1201.
5.
Rivière J, Bernhard JC, Robert G, Wallerand H, Deti E, Maurice-Tison S, Ardiet JM, Maire JP, Richaud P, Ferriere JM, Ballanger P, Gelet A, Pasticier G: Salvage radiotherapy after high-intensity focused ultrasound for recurrent localised prostate cancer. Eur Urol 2010;58:567-573.
6.
Pasticier G, Chapet O, Badet L, Ardiet JM, Poissonnier L, Murat FJ, Martin X, Gelet A: Salvage radiotherapy after high focused ultrasound for localized prostate cancer: early clinical results. Urology 2008;72:1305-1309.
7.
Ripert T, Bayoud Y, Messaoudi R, Ménard J, Azémar MD, Duval F, Nguyen TD, Staerman F: Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy. Can Urol Assoc J 2012;6:E179-E183.
8.
D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;7:168-172.
9.
Hanlon AL, Schultheiss TE, Hunt MA, et al: Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys 1997;38:59-63.
10.
Storey MR, Pollack A, Zagars G, et al: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-642.
11.
Ingelman-Sundberg A, Ulmsten U: Surgical treatment of female urinary stress incontinence. Contrib Gynecol Obstet 1983;10:51-69.
12.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
13.
Mearini L, D'Urso L, Collura D, Zucchi A, Costantini E, Formiconi A, Bini V, Muto G, Porena M: Visually directed transrectal high-intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 2009;181:105-111.
14.
Leonardo C, Franco G, De Nunzio C, Tubaro A, Salvitti M, Tartaglia N, Simonelli G, De Dominicis C: Salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer. Urology 2012;80:130-133.
15.
Lawrentschuk N, Finelli A, Van der Kwast TH, Ryan P, Bolton DM, Fleshner NE, Trachtenberg J, Klotz L, Robinette M, Woo H: Salvage radical prostatectomy following primary high-intensity focused ultrasound for treatment of prostate cancer. J Urol 2011;185:862-868.
16.
Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI: Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-1129.
17.
Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic Experience. Int J Radiat Oncol Biol Phys 2007;68:1424-1430.
18.
Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A: Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU Int 2011;108:E196-E201.
19.
Ray ME, Thames HD, Levy LB, et al: PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006;64:1140-1150.
20.
Ko EC, Stone NN, Stock RG: PSA nadir of <0.5 ng/ml following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 2012;83:600-607.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.